Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency

加药 医学 药代动力学 内科学 生长激素缺乏 四分位间距 药效学 内分泌学 人口 生长激素 激素替代疗法(女性对男性) 生长激素 激素 环境卫生 睾酮(贴片)
作者
Rasmus Juul Kildemoes,Christian Hollensen,Beverly M. K. Biller,Gudmundur Johannsson,Yutaka Takahashi,Michael Højby Rasmussen
出处
期刊:European journal of endocrinology [Oxford University Press]
卷期号:187 (1): 27-38 被引量:4
标识
DOI:10.1530/eje-21-1167
摘要

Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose-responses among patients. The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH derivative somapacitan based on analyses of somapacitan dose-insulin-like growth factor I (IGF-I) responses in AGHD patients.Analyses of dosing information, 4364 somapacitan concentration samples and 4880 IGF-I samples from 330 AGHD patients treated with somapacitan in three phase 3 trials.Pharmacokinetic/pharmacodynamic modelling was used to evaluate starting dose groups by age and oral oestrogen therapy, characterise the dose-IGF-I response in the overall AGHD population and patient subgroups, predict the IGF-I response to dose changes and simulate missed dosing.The analyses supported the clinical recommendations of higher starting doses for younger patients and women on oral oestrogen replacement therapy. For patients switching from daily GH treatment, the mean maintenance dose ratio between somapacitan (mg/week) and somatropin (mg/day) was predicted to be 8.2 (observed interquartile range of 6.7-9.1). Simulations of IGF-I SDS profiles confirmed the appropriate time for IGF-I sampling to be 3-4 days after somapacitan dosing and supported somapacitan administration with up to 3 days delay in case of missed dosing. Subgroup analyses characterised the dose-exposure-IGF-I response in patient subgroups and indicated that dose requirements are mainly influenced by sex and oral oestrogen treatment.This study extends the knowledge of the somapacitan dose-IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
好困发布了新的文献求助10
刚刚
1秒前
科研通AI2S应助一一一采纳,获得10
1秒前
Tianju发布了新的文献求助10
1秒前
许晓蝶完成签到,获得积分10
1秒前
2秒前
3秒前
3秒前
岑广山发布了新的文献求助10
3秒前
丘比特应助CMJ采纳,获得10
4秒前
4秒前
RUINNNO完成签到,获得积分10
4秒前
fffffffq发布了新的文献求助10
4秒前
大美女完成签到,获得积分10
5秒前
5秒前
墨羽完成签到,获得积分20
5秒前
6秒前
英俊的铭应助玖Nine采纳,获得10
6秒前
6秒前
6秒前
欢喜的小海豚完成签到,获得积分10
7秒前
一一一完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
8秒前
背后大白发布了新的文献求助10
9秒前
今后应助东北雨姐采纳,获得30
9秒前
山南有木兮完成签到,获得积分10
9秒前
9秒前
wyn完成签到,获得积分10
9秒前
mx应助xiaohaitao采纳,获得10
10秒前
墨羽发布了新的文献求助10
10秒前
烂漫梦容发布了新的文献求助10
11秒前
lin发布了新的文献求助10
11秒前
11秒前
今后应助无心的满天采纳,获得10
11秒前
涵泽发布了新的文献求助10
12秒前
我是老大应助lijianguo采纳,获得10
13秒前
sky完成签到,获得积分10
14秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961589
求助须知:如何正确求助?哪些是违规求助? 3507917
关于积分的说明 11138698
捐赠科研通 3240341
什么是DOI,文献DOI怎么找? 1790929
邀请新用户注册赠送积分活动 872649
科研通“疑难数据库(出版商)”最低求助积分说明 803306